Austin K Mattox1, Beibei Yang2, Christopher Douville1, Sheng-Fu Lo3, Daniel Sciubba3, Jean Paul Wolinsky4, Ziya L Gokaslan5, Jamie Robison6, Cherie Blair1, Yuchen Jiao2, Chetan Bettegowda1,3,7. 1. Ludwig Center for Cancer Genetics and Therapeutics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of Neurosurgery, Northwestern University School of Medicine, Chicago, Illinois, USA. 5. Department of Neurosurgery, Brown University School of Medicine, Providence, Rhode Island, USA. 6. Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida, USA. 7. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Chordomas are the most common primary spinal column malignancy in the United States. The aim of this study was to determine whether chordomas may be detected by evaluating mutations in circulating tumor DNA (ctDNA). METHODS: Thirty-two patients with a biopsy-confirmed diagnosis of chordoma had blood drawn pre-operatively and/or at follow-up appointments. Mutations in the primary tumor were identified by whole exome sequencing and liquid biopsy by ddPCR and/or RACE-Seq was used to detect one or more of these mutations in plasma ctDNA at concurrent or later time points. RESULTS: At the time of initial blood draw, 87.1% of patients were ctDNA positive (P <.001). Follow-up blood draws in twenty of the patients suggest that ctDNA levels may reflect the clinical status of the disease. Patients with positive ctDNA levels were more likely to have greater mutant allele frequencies in their primary tumors (P = .004) and undergo radiotherapy (P = .02), and the presence of ctDNA may correlate with response to systemic chemotherapy and/or disease recurrence. CONCLUSIONS: Detection of ctDNA mutations may allow for the detection and monitoring of disease progression for chordomas.
BACKGROUND: Chordomas are the most common primary spinal column malignancy in the United States. The aim of this study was to determine whether chordomas may be detected by evaluating mutations in circulating tumor DNA (ctDNA). METHODS: Thirty-two patients with a biopsy-confirmed diagnosis of chordoma had blood drawn pre-operatively and/or at follow-up appointments. Mutations in the primary tumor were identified by whole exome sequencing and liquid biopsy by ddPCR and/or RACE-Seq was used to detect one or more of these mutations in plasma ctDNA at concurrent or later time points. RESULTS: At the time of initial blood draw, 87.1% of patients were ctDNA positive (P <.001). Follow-up blood draws in twenty of the patients suggest that ctDNA levels may reflect the clinical status of the disease. Patients with positive ctDNA levels were more likely to have greater mutant allele frequencies in their primary tumors (P = .004) and undergo radiotherapy (P = .02), and the presence of ctDNA may correlate with response to systemic chemotherapy and/or disease recurrence. CONCLUSIONS: Detection of ctDNA mutations may allow for the detection and monitoring of disease progression for chordomas.
Authors: Christopher Douville; Joshua D Cohen; Janine Ptak; Maria Popoli; Joy Schaefer; Natalie Silliman; Lisa Dobbyn; Robert E Schoen; Jeanne Tie; Peter Gibbs; Michael Goggins; Christopher L Wolfgang; Tian-Li Wang; Ie-Ming Shih; Rachel Karchin; Anne Marie Lennon; Ralph H Hruban; Cristian Tomasetti; Chetan Bettegowda; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein Journal: Proc Natl Acad Sci U S A Date: 2020-02-19 Impact factor: 11.205
Authors: Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn Journal: Cancer Discov Date: 2017-09-24 Impact factor: 39.397
Authors: Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs Journal: Sci Transl Med Date: 2016-07-06 Impact factor: 17.956
Authors: Lu Wang; Ahmet Zehir; Khedoudja Nafa; Nengyi Zhou; Michael F Berger; Jacklyn Casanova; Justyna Sadowska; Chao Lu; C David Allis; Mrinal Gounder; Chandhanarat Chandhanayingyong; Marc Ladanyi; Patrick J Boland; Meera Hameed Journal: Genes Chromosomes Cancer Date: 2016-05-09 Impact factor: 5.006
Authors: Damian Szklarczyk; Andrea Franceschini; Stefan Wyder; Kristoffer Forslund; Davide Heller; Jaime Huerta-Cepas; Milan Simonovic; Alexander Roth; Alberto Santos; Kalliopi P Tsafou; Michael Kuhn; Peer Bork; Lars J Jensen; Christian von Mering Journal: Nucleic Acids Res Date: 2014-10-28 Impact factor: 16.971
Authors: Julien Lagarde; Barbara Uszczynska-Ratajczak; Javier Santoyo-Lopez; Jose Manuel Gonzalez; Electra Tapanari; Jonathan M Mudge; Charles A Steward; Laurens Wilming; Andrea Tanzer; Cédric Howald; Jacqueline Chrast; Alicia Vela-Boza; Antonio Rueda; Francisco J Lopez-Domingo; Joaquin Dopazo; Alexandre Reymond; Roderic Guigó; Jennifer Harrow Journal: Nat Commun Date: 2016-08-17 Impact factor: 14.919
Authors: Chetan Bettegowda; Stephen Yip; Bowen Jiang; Wei-Lien Wang; Michelle J Clarke; Aron Lazary; Marco Gambarotti; Ming Zhang; Daniel M Sciubba; Jean-Paul Wolinsky; C Rory Goodwin; Edward McCarthy; Niccole M Germscheid; Arjun Sahgal; Ziya L Gokaslan; Stefano Boriani; Peter Pal Varga; Charles G Fisher; Laurence D Rhines Journal: Neuro Oncol Date: 2019-08-05 Impact factor: 12.300